Retroperitoneal Sarcoma
On this page
Direct answer
Silent until large — a retroperitoneal sarcoma typically presents as a huge, painless abdominal mass (or with vague bloating, early satiety or leg oedema from iliac vein compression) discovered on examination or imaging, with liposarcoma (well-differentiated and dedifferentiated) the commonest histology and leiomyosarcoma next. Management is fundamentally surgical: complete resection, which in practice means en bloc multivisceral resection — taking the kidney, colon, spleen, pancreatic tail or psoas fascia wherever the tumour is adherent, because the apparent "capsule" of a retroperitoneal sarcoma is a pseudocapsule of compressed tumour and shelling along it leaves disease — with margin status the strongest predictor of local recurrence and survival. Radiotherapy has an uncertain role (a large randomised trial of preoperative radiotherapy did not improve outcomes overall), chemotherapy is largely palliative, and referral to a specialist sarcoma centre before the first operation is the single most consequential decision, since the first operation offers the best — often the only — chance of cure.
What you must remember
- Presentation: slow-growing deep mass — abdominal fullness, early satiety, obstructive symptoms, varicocele or leg swelling (iliac compression), neuropathic pain radiating to the thigh (psoas/nerve involvement); frequently an incidental finding or a palpable mass reaching 10–20 cm before diagnosis.
- Histology: liposarcoma commonest (well-differentiated liposarcoma low grade with dedifferentiated high-grade components in the same mass — MDM2 amplification by FISH distinguishes it from lipoma), leiomyosarcoma (often vascular, IVC involvement produces Budd-Chiari-like syndromes), solitary fibrous tumour, desmoid (a differential, not a sarcoma, managed elsewhere), and in India account must be taken of tuberculous psoas abscess and hydatid in the retroperitoneal-mass differential.
- Imaging: contrast CT abdomen-pelvis (and chest CT for staging — lung is the metastatic target, though peritoneal and hepatic spread occur) defining organ invasion, vessel encasement and the contralateral kidney; MRI adds soft-tissue plane and vessel detail; core biopsy via a tract that will be excised (transperitoneal or posterior, never through uninvolved compartments) — biopsy is safe and recommended before neoadjuvant decisions.
- The operative principle: resect the tumour en bloc with all adherent organs and structures to achieve a microscopically negative margin — commonly including kidney, adrenal, colon, spleen, distal pancreas, psoas muscle; dividing the renal vessels or IVC needs planning (IVC ligation or graft reconstruction when involved; contralateral renal function must be confirmed first).
- Do not rely on the pseudocapsule: marginal ("shelling out") resections carry high local recurrence; most series attribute the survival gradient to completeness of resection (complete versus incomplete/debulking) — yet debulking still has a place in selected low-grade liposarcoma for symptom control, a nuance worth stating.
- Radiotherapy: preoperative external beam (as tested in the EORTC-1809/STRASS trial) did not improve abdominal recurrence-free survival overall — so its routine use is questioned, though selected centres continue it for high-grade lesions; intraoperative radiotherapy and intensity-modulated techniques are centre-specific.
- Chemotherapy: palliative for metastatic or unresectable disease (anthracycline-based); no established adjuvant standard for most adult histologies.
- Recurrence: local recurrence is the dominant failure pattern (especially dedifferentiated liposarcoma), often years later — surveillance with periodic CT for at least 5–10 years, and resection of isolated recurrences in fit patients offers meaningful further survival.
- Centre effect: outcomes are better in high-volume sarcoma centres; the practical exam answer for an undiagnosed retroperitoneal mass is imaging, core biopsy, and referral before any operation.
A typical case walked through
A 55-year-old woman reports six months of left flank fullness and constipation; examination finds a firm left upper quadrant mass, and contrast CT shows a 16 cm heterogeneous fatty tumour sweeping the left retroperitoneum, adherent to the left kidney, descending colon and pancreatic tail, with a solid nodular component — the imaging signature of dedifferentiated liposarcoma. Walk the plan: chest CT (clear), core biopsy confirming dedifferentiated liposarcoma with MDM2 amplification; renal isotope or CT assessment of the right kidney. She is counselled for an en bloc resection — tumour with left kidney, adrenal, distal pancreas, spleen and left colon segment — through a midline or left flank approach, vascular control planned for the renal vessels, with the aim of an unviolated tumour plane and microscopically negative margins; a feeding route and bowel preparation anticipate the colonic anastomosis. Margins are negative; she enters CT surveillance because local recurrence remains likely over the next decade. The forks: the same tumour encasing the aorta and both renal hila in a frail patient is unresectable-with-margin disease — biopsy-proven, she is offered chemotherapy and symptom-directed care rather than a risky marginal excision; a low-grade well-differentiated liposarcoma causing pressure symptoms in an elderly patient may justify a debulking philosophy, accepting recurrence, which is a legitimate, stated exception to the margin rule.
Where students slip
Two errors recur. The first is the reflex to "shell the tumour out" — in retroperitoneal sarcoma the pseudocapsule is tumour-bearing compressed tissue, and the mark-winning phrase is en bloc multivisceral resection with negative margins. The second is presenting radiotherapy as standard adjuvant therapy — the contemporary answer acknowledges the negative STRASS trial and the selective, centre-specific role of radiation. Students also forget the differential: in Indian practice a psoas abscess or hydatid cyst masquerading as a retroperitoneal mass deserves a sentence, and MDM2 FISH is the molecular test separating liposarcoma from lipoma in difficult biopsies.
Frequently asked questions
Which histologies predominate in the retroperitoneum?
Liposarcoma (well-differentiated and dedifferentiated) is commonest, followed by leiomyosarcoma; dedifferentiated components make an otherwise low-grade tumour high grade.
Why is multivisceral en bloc resection the standard operation?
The apparent capsule is a pseudocapsule containing tumour satellites; clearing the tumour requires resecting adherent organs (kidney, colon, spleen, pancreatic tail, psoas) with it, and margin status is the strongest determinant of local control and survival.
What did the STRASS trial show about preoperative radiotherapy?
It did not improve abdominal recurrence-free survival overall in retroperitoneal sarcoma, so routine preoperative radiotherapy is now questioned, though selected high-grade use continues in some centres.
How is a retroperitoneal mass worked up before surgery?
Contrast CT of abdomen and chest (staging and resectability), MRI for vessel and plane detail, core biopsy along a resectable tract, and confirmation of contralateral renal function before any nephrectomy.
How are patients followed after resection?
Periodic CT of abdomen and chest for at least 5 years (many extend to 10), because local recurrence — especially of dedifferentiated liposarcoma — occurs late and resectable recurrences are worth detecting.